IP Library › Assignment 016378/0443
Patent Assignment
Reel/Frame 016378/0443

Change of Name

Recorded: 2005-03-21 Pages: 21
Assignor
RIBOZYME PHARMACEUTICALS, INC.
Executed: 2003-04-16
Assignee
SIRNA THERAPEUTICS, CIN
2950 WILDERNESS PLACE, BOULDER, COLORADO, 80301
Covered Property (1)
Enzymatic Nucleic Acid-Mediated Treatment of Ocular Diseases or Conditions Related to Levels of Vascular Endothelial Growth Factor Receptor (Vegf-R)
Patent: 7,034,009 →
Application: 10/138,674 →
Publication: US 2004/0077565
Related Assignments (3)
Other recorded transfers of the patent in this record — the chain of ownership.
Assignment of Assignor's Interest Aug 13, 2002
From: PAVCO, PAMELA; MCSWIGGEN, JAMES; STINCHCOMB, DAN
To: RIBOZYME PHARMACEUTICALS, INC.
Reel/Frame 013182/0220 →
Assignment of Assignor's Interest Aug 13, 2002
From: ESCOBEDO, JAIME
To: CHIRON CORPORATION, INC.
Reel/Frame 013182/0308 →
Corrective Name Change to Correct Assignee's Name Previously Recorded at Reel 016378 Frame 0443. Oct 5, 2005
From: RIBOZYME PHARMACEUTICALS, INC.
To: SIRNA THERAPEUTICS, INC.
Reel/Frame 016854/0262 →